Day One

• Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen the therapeutic index and bring patient benefit
• Showcasing late-breaking clinical data from novel tumour targets in underserved populations
• Highlighting future priorities for next-generation ADC development with differentiated safety profiles and future standard of care therapies

• Advancing next-generation dual-payload ADCs to address traditional challenges like drug resistance and narrow therapeutic windows
• Leveraging WuXiDARx™ technology for flexible DAR1-6 and WuXiTecan2™ hydrophilic linker, enabling streamlined dual-payload construction without antibody engineering
• Demonstrating a substantially wider therapeutic index alongside significantly enhanced anti-tumor efficacy in proof-of-concept studies

• Understanding the 2027 ADC landscape and how the bar has been raised to develop and deliver ADCs with meaningful patient impact
• Outlining the future opportunities and applications on the horizon for ADCs to achieve target differentiation and clinical safety
• Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
• With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the ADC field and establish meaningful business relationships to pursue for the rest of the conference. Connect with your peers using the dedicated Event App, in-person private meetings or at the coffee stations in the exhibition space!